Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upChronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticariaActive, not recruitingPhase 32026-10-02NCT05677451

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Novartis Pharmaceuticals432

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Allergy and Asthma Medical Group and Research CenterSan DiegoUnited States2
Allergy and Asthma Specialist P S COwensboroUnited States4
Allergy and Clinical Immunology AssociatesPittsburghUnited States8
Allergy Associates of UtahSandy CityUnited States6
Allergy Asthma and Clinical ResearchOklahoma CityUnited States3
Endeavor HealthGlenviewUnited States6
Kern ResearchBakersfieldUnited States5
Pediatric Dermatology of Miami at the Pediatric CoEMiamiUnited States1
RFSA DermatologySan AntonioUnited States6
Toledo Institute of Clinical ResearchToledoUnited States6
Treasure Valley Medical ResearchBoiseUnited States21